Halder Venture Limited Announces Postal Ballot for Capital Increase and Convertible Warrants Issue

3 min read     Updated on 30 Mar 2026, 10:18 PM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

Halder Venture Limited has issued a postal ballot notice for two key corporate actions. The company seeks to increase authorized share capital from Rs. 13.42 crore to Rs. 18.42 crore and issue 7,93,650 convertible warrants at Rs. 315 per warrant to raise Rs. 25 crore from P.K. Bio Link Pvt. Ltd. E-voting runs from March 31 to April 29, 2026, with results by May 1, 2026.

powered bylight_fuzz_icon
36434914

*this image is generated using AI for illustrative purposes only.

Halder Venture Limited has announced a postal ballot notice seeking shareholder approval for significant corporate restructuring initiatives. The company has proposed two key resolutions that will enhance its capital structure and funding capabilities.

Authorized Share Capital Enhancement

The company seeks approval to increase its authorized share capital substantially. The proposed enhancement involves expanding the capital base to accommodate future growth and conversion requirements.

Parameter: Current Structure Proposed Structure
Authorized Capital: Rs. 13,42,50,000 Rs. 18,42,50,000
Number of Shares: 1,34,25,000 1,84,25,000
Additional Shares: - 50,00,000
Face Value: Rs. 10 per share Rs. 10 per share

The increase in authorized share capital requires alteration to Clause V of the company's Memorandum of Association. This expansion will provide adequate headroom for the proposed convertible warrants and future capital requirements.

Convertible Warrants Issuance

The company proposes to issue convertible warrants on a preferential basis to non-promoter entities. The warrants will provide holders the right to convert into equity shares within a specified timeframe.

Details: Specifications
Number of Warrants: 7,93,650
Issue Price: Rs. 315 per warrant
Premium: Rs. 305 per warrant
Total Amount: Rs. 24,99,99,750
Allottee: P.K. Bio Link Pvt. Ltd.
Conversion Period: 18 months from allotment

Pricing and Valuation Framework

Since the company's equity shares are infrequently traded, the pricing follows SEBI ICDR Regulation 165 requirements. An independent registered valuer, CA Sanjay Jhajharia, conducted the valuation assessment.

Valuation Parameter: Amount
Minimum Price (Valuation Report): Rs. 314.79 per share
Approved Issue Price: Rs. 315 per share
Payment at Allotment: 25% of issue price
Balance Payment: 75% at conversion

Fund Utilization Strategy

The company plans to deploy the raised funds across two primary objectives, with equal allocation for each purpose.

Purpose: Allocation Timeline
Capital Expansion: Rs. 12,49,99,875 Within 6 months
Working Capital: Rs. 12,49,99,875 Within 6 months
Total: Rs. 24,99,99,750 -

The capital expansion funds will support business operations expansion, network strengthening, and strategic investments. Working capital augmentation will improve the company's overall financial health and support general corporate purposes.

Shareholding Impact Analysis

The preferential issue will result in shareholding pattern changes, with P.K. Bio Link Pvt. Ltd. acquiring a significant stake upon full conversion.

Shareholding Category: Pre-Issue (%) Post-Issue (%)
Promoter & Promoter Group: 73.70% 69.28%
Public Shareholding: 26.30% 30.72%
P.K. Bio Link Pvt. Ltd.: 0% 5.99%

The ultimate beneficial owners of P.K. Bio Link Pvt. Ltd. are Pronoy Bhattacharyya and Pritikona Bhattacharya. The transaction will not result in any change of control or management.

Voting and Timeline Details

The postal ballot process follows electronic voting procedures, with specific timelines established for shareholder participation.

Timeline Parameter: Date/Period
Record Date: March 27, 2026
E-voting Commencement: March 31, 2026 (10:00 AM)
E-voting Conclusion: April 29, 2026 (5:00 PM)
Results Declaration: By May 1, 2026
Warrant Allotment: Within 15 days of approval

Mr. Manoj Prasad Shaw, Practicing Company Secretary, has been appointed as the scrutinizer for the e-voting process. The company will conduct the entire voting process electronically, with notices sent only to shareholders with registered email addresses.

The resolutions require different approval thresholds - the capital increase needs ordinary resolution approval, while the convertible warrants issuance requires special resolution approval from shareholders.

Historical Stock Returns for Halder Venture

1 Day5 Days1 Month6 Months1 Year5 Years
+4.18%+0.40%+1.10%-7.11%-7.11%-7.11%

How will the significant capital infusion of Rs. 25 crores impact Halder Venture's competitive position and market expansion plans in their industry sector?

What strategic synergies might emerge from P.K. Bio Link's 5.99% stake acquisition, given the biotech connection suggested by their company name?

Will the improved public shareholding ratio of 30.72% make Halder Venture more attractive to institutional investors and improve stock liquidity?

Halder Venture Limited Pays Rs. 5,42,800 BSE Fine for Board Composition Non-Compliance

1 min read     Updated on 27 Mar 2026, 08:51 PM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

Halder Venture Limited has paid a regulatory fine of Rs. 5,42,800 imposed by BSE for violating board composition requirements under SEBI Regulation 17(1) for the quarter ended September 2025. The company made the payment on March 26, 2026, following receipt of the BSE order on March 18, 2026, and disclosed that there is no financial impact beyond the fine amount.

powered bylight_fuzz_icon
36170478

*this image is generated using AI for illustrative purposes only.

Halder venture Limited has paid a regulatory fine of Rs. 5,42,800 imposed by the Bombay Stock Exchange (BSE) for non-compliance with board composition requirements under SEBI regulations. The payment was made on March 26, 2026, as disclosed by the company in its regulatory filing dated March 27, 2026.

Regulatory Violation Details

The fine was imposed for non-compliance of Regulation 17(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 pertaining to the composition of the Board of Directors for the quarter ended September 2025. The company received the BSE order via email on March 18, 2026 at 4:41 PM.

Fine Payment Information

The following table provides complete details of the regulatory action and payment:

Parameter: Details
Authority: Bombay Stock Exchange (BSE)
Fine Amount: Rs. 5,42,800 (including GST)
Violation: Non-compliance of Regulation 17(1) - Board composition
Period: Quarter ended September 2025
Order Receipt Date: March 18, 2026
Payment Date: March 26, 2026
Payment Method: RTGS/NEFT via ICICI Bank
UTR Number: INF/INFT/774529182646/BSER11070/ICICI Bank

Compliance Disclosure

The disclosure was made pursuant to Regulation 30 read with Clause 20 of Para A Part A of Schedule III of the SEBI LODR and updated SEBI Master Circular No: HO/49/14/14(7)2025-CFD-POD2/1/3762/2026 dated January 30, 2026. This follows the company's earlier disclosure dated March 19, 2026 regarding rejection of waiver application and imposition of the SOP fine by BSE.

Financial Impact

According to the company's disclosure, there is no impact on financial, operational or other activities of the listed entity except to the extent of the fine amount of Rs. 5,42,800 including GST imposed by BSE. The payment was authorized by Company Secretary and Compliance Officer Ayanti Sen, who signed the disclosure document digitally on March 27, 2026.

Historical Stock Returns for Halder Venture

1 Day5 Days1 Month6 Months1 Year5 Years
+4.18%+0.40%+1.10%-7.11%-7.11%-7.11%

What specific board composition changes will Halder Venture implement to prevent future SEBI regulation violations?

Could this compliance violation impact Halder Venture's ability to raise capital or attract institutional investors in the coming quarters?

Will SEBI introduce stricter monitoring mechanisms for board composition compliance following recent violations across listed companies?

More News on Halder Venture

1 Year Returns:-7.11%